Nueva plaza de Erlangen - Alemania Federal

Not available<br><br>El proyecto de la nueva plaza de Erlangen abarca los siguientes edificios: AYUNTAMIENTO, que aloja la sala principal y todas las instalaciones correspondientes. HOTEL DE 1.ª CATEGORÍA, con una capacidad de 240 camas repartidas en 138 habitaciones. Entre sus servicios se hallan: restaurante; piscina cubierta; sauna; salones de conferencias; e instalaciones centrales de cocina para el hotel y la sala Municipal. SALA MUNICIPAL, que alberga una gran sala de 1.203 asientos; sala pequeña con 270 asientos; sala da descanso; camerinos de artistas; restaurante de 180 plazas, y salas de conferencias. CENTRO COMERCIAL, con 45 locales comerciales de una y dos plantas. ALMACÉN GENERAL, con una superficie de unos 7.500 m². APARCAMIENTO, con 650 plazas repartidas en 10 niveles, y estación de servicio. La oficina de Harald Loebermann proyectó, dirigió y decoró todos los locales. La ciudad se hizo cargo de la financiación y realización de las obras del Ayuntamiento, encargándose de las restantes construcciones la Firma alemana Aniagen Leasing

Confocal Laser Scanning Microscopy, a New In Vivo Diagnostic Tool for Schistosomiasis

BACKGROUND: The gold standard for the diagnosis of schistosomiasis is the detection of the parasite's characteristic eggs in urine, stool, or rectal and bladder biopsy specimens. Direct detection of eggs is difficult and not always possible in patients with low egg-shedding rates. Confocal laser scanning microscopy (CLSM) permits non-invasive cell imaging in vivo and is an established way of obtaining high-resolution images and 3-dimensional reconstructions. Recently, CLSM was shown to be a suitable method to visualize Schistosoma mansoni eggs within the mucosa of dissected mouse gut. In this case, we evaluated the suitability of CLSM to detect eggs of Schistosoma haematobium in a patient with urinary schistosomiasis and low egg-shedding rates. METHODOLOGY/PRINCIPAL FINDINGS: The confocal laser scanning microscope used in this study was based on a scanning laser system for imaging the retina of a living eye, the Heidelberg Retina Tomograph II, in combination with a lens system (image modality). Standard light cystoscopy was performed using a rigid cystoscope under general anaesthesia. The CLSM endoscope was then passed through the working channel of the rigid cystoscope. The mucosal tissue of the bladder was scanned using CLSM. Schistoma haematobium eggs appeared as bright structures, with the characteristic egg shape and typical terminal spine. CONCLUSION/SIGNIFICANCE: We were able to detect schistosomal eggs in the urothelium of a patient with urinary schistosomiasis. Thus, CLSM may be a suitable tool for the diagnosis of schistosomiasis in humans, especially in cases where standard diagnostic tools are not suitable

Meta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines

Background: Although the 2009 (H1N1) influenza pandemic officially ended in August 2010, the virus will probably circulate in future years. Several types of H1N1 vaccines have been tested including various dosages and adjuvants, and meta-analysis is needed to identify the best formulation. Methods: We searched MEDLINE, EMBASE, and nine clinical trial registries to April 2011, in any language for randomized clinical trials (RCTs) on healthy children, adolescents, adults and the elderly. Primary outcome was the seroconversion rate according to hemagglutinination-inhibition (HI); secondary outcomes were adverse events. For the primary outcome, we used head-to-head meta-analysis and multiple-treatments meta-analysis. Results: Eighteen RCTs could be included in all primary analyses, for a total of 76 arms (16,725 subjects). After 2 doses, all 2009 H1N1 split/subunit inactivated vaccines were highly immunogenic and overcome CPMP seroconversion criteria. After 1 dose only, all split/subunit vaccines induced a satisfactory immunogenicity (> = 70%) in adults and adolescents, while only some formulations showed acceptable results for children and elderly (non-adjuvanted at high-doses and oil-in-water adjuvanted vaccines). Vaccines with oil-in-water adjuvants were more immunogenic than both nonadjuvanted and aluminum-adjuvanted vaccines at equal doses and their immunogenicity at doses < = 6 μg (even with as little as 1.875 μg of hemagglutinin antigen) was not significantly lower than that achieved after higher doses. Finally, the rate of serious vaccine-related adverse events was low for all 2009 H1N1 vaccines (3 cases, resolved in 10 days, out of 22826 vaccinated subjects). However, mild to moderate adverse reactions were more (and very) frequent for oil-in-water adjuvanted vaccines. Conclusions: Several one-dose formulations might be valid for future vaccines, but 2 doses may be needed for children, especially if a low-dose non-adjuvanted vaccine is used. Given that 15 RCTs were sponsored by vaccine manufacturers, future trials sponsored by non-industry agencies and comparing vaccines using different types of adjuvants are needed

Cross-Lineage Influenza B and Heterologous Influenza A Antibody Responses in Vaccinated Mice: Immunologic Interactions and B/Yamagata Dominance

The annually reformulated trivalent inactivated influenza vaccine (TIV) includes both influenza A/subtypes (H3N2 and H1N1) but only one of two influenza B/lineages (Yamagata or Victoria). In a recent series of clinical trials to evaluate prime-boost response across influenza B/lineages, influenza-naïve infants and toddlers originally primed with two doses of 2008–09 B/Yamagata-containing TIV were assessed after two doses of B/Victoria-containing TIV administered in the subsequent 2009–10 and 2010–11 seasons. In these children, the Victoria-containing vaccines strongly recalled antibody to the initiating B/Yamagata antigen but induced only low B/Victoria antibody responses. To further evaluate this unexpected pattern of cross-lineage vaccine responses, we conducted additional immunogenicity assessment in mice. In the current study, mice were primed with two doses of 2008–09 Yamagata-containing TIV and subsequently boosted with two doses of 2010–11 Victoria-containing TIV (Group-Yam/Vic). With the same vaccines, we also assessed the reverse order of two-dose Victoria followed by two-dose Yamagata immunization (Group-Vic/Yam). The Group-Yam/Vic mice showed strong homologous responses to Yamagata antigen. However, as previously reported in children, subsequent doses of Victoria antigen substantially boosted Yamagata but induced only low antibody response to the immunizing Victoria component. The reverse order of Group-Vic/Yam mice also showed low homologous responses to Victoria but subsequent heterologous immunization with even a single dose of Yamagata antigen induced substantial boost response to both lineages. For influenza A/H3N2, homologous responses were comparably robust for the differing TIV variants and even a single follow-up dose of the heterologous strain, regardless of vaccine sequence, substantially boosted antibody to both strains. For H1N1, two doses of 2008–09 seasonal antigen significantly blunted response to two doses of the 2010–11 pandemic H1N1 antigen. Immunologic interactions between influenza viruses considered antigenically distant and in particular the cross-lineage influenza B and dominant Yamagata boost responses we have observed in both human and animal studies warrant further evaluation

Long-term safety and efficacy of Eculizumab in Aquaporin-4 IgG-positive NMOSD

Objective During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk versus placebo in patients with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD). We report an interim analysis of PREVENT's ongoing open-label extension (OLE; NCT02003144) evaluating eculizumab's long-term safety and efficacy. Methods Patients who completed PREVENT could enroll in the OLE to receive eculizumab (maintenance dose = 1,200 mg/2 weeks, after a blinded induction phase). Safety and efficacy data from PREVENT and its OLE (interim data cut, July 31, 2019) were combined for this analysis. Results Across PREVENT and the OLE, 137 patients received eculizumab and were monitored for a median (range) of 133.3 weeks (5.1–276.9 weeks), for a combined total of 362.3 patient-years (PY). Treatment-related adverse event (AE) and serious adverse event (SAE) rates were 183.5 in 100 PY and 8.6 in 100 PY, respectively. Serious infection rates were 10.2 in 100 PY in eculizumab-treated patients versus 15.1 in 100 PY in the PREVENT placebo group. No patient developed a meningococcal infection. At 192 weeks (3.7 years), 94.4% (95% confidence interval [CI], 88.6–97.3) of patients remained adjudicated relapse-free. The adjudicated annualized relapse rate was 0.025 (95% CI = 0.013–0.048) in all eculizumab-treated patients versus 0.350 (95% CI = 0.199–0.616) in the PREVENT placebo group. During the OLE, 37% of patients (44 of 119 patients) stopped or decreased background immunosuppressive therapy use. Interpretation This analysis demonstrates that eculizumab's long-term safety profile in NMOSD is consistent with its established profile across other indications. This analysis also demonstrated the sustained ability of long-term eculizumab treatment to reduce relapse risk in patients with AQP4-IgG+ NMOSD. ANN NEUROL 2021;89:1088–109

Sala Maestros Cantores - Nuremberg (Alemania)

The Concert Hall is reached through the entrance vestibule, cloak room area and large foyer from which a spacious patio, treated as landscape, can be seen. Thus, the outside environment is incorporated Into the inside environment which lends great beauty to the unit formed by the entrance area and the foyer while at the same time it establishes a clear separation of the different functions that take place Inside. On this floor there is also another concert room, smaller in size as it holds only 500 persons, with its own foyer, bar, cloak room, etc.; a wide restaurant area, which can be widened towards the outdoor terraces; kitchens; meeting and rehearsal rooms, etc. With regards to the surrounding zone, the green areas existing or created around the Concert Hall help to maintain and emphasize its park like character, already helped by the «Leopold Forest» within which the site is found.<br><br>El acceso a la Sala de Conciertos se realiza a través del vestíbulo de entrada, zona de guardarropas y gran «foyer» —en comunicación visual con un amplio patio tratado paisajísticamente, lográndose una incorporación del ambiente exterior, al del interior—, lo que da una gran vistosidad al conjunto formado por la zona de entrada y foyer, al mismo tiempo que establece una clara separación de las diferentes funciones que se desarrollan en el interior. En esta planta hay, además, otra sala de conciertos más pequeña —capaz para 500 personas—, con sus correspondientes foyer, bar, guardarropas, etc.; una amplia zona de restaurante —ampliable hacia las terrazas exteriores—; cocinas; salas de juntas, de ensayos; etc. Respecto al entorno exterior, las zonas verdes existentes o creadas alrededor de la Sala de Conciertos contribuyen a mantener y acusar el carácter de «parque», que ya ofrecía el «Bosque de Leopoldo» —lugar del emplazamiento—

Nueva plaza de Erlangen - Alemania Federal

Not availableEl proyecto de la nueva plaza de Erlangen abarca los siguientes edificios: AYUNTAMIENTO, que aloja la sala principal y todas las instalaciones correspondientes. HOTEL DE 1.ª CATEGORÍA, con una capacidad de 240 camas repartidas en 138 habitaciones. Entre sus servicios se hallan: restaurante; piscina cubierta; sauna; salones de conferencias; e instalaciones centrales de cocina para el hotel y la sala Municipal. SALA MUNICIPAL, que alberga una gran sala de 1.203 asientos; sala pequeña con 270 asientos; sala da descanso; camerinos de artistas; restaurante de 180 plazas, y salas de conferencias. CENTRO COMERCIAL, con 45 locales comerciales de una y dos plantas. ALMACÉN GENERAL, con una superficie de unos 7.500 m2. APARCAMIENTO, con 650 plazas repartidas en 10 niveles, y estación de servicio. La oficina de Harald Loebermann proyectó, dirigió y decoró todos los locales. La ciudad se hizo cargo de la financiación y realización de las obras del Ayuntamiento, encargándose de las restantes construcciones la Firma alemana Aniagen Leasing